加拿大卫生技术评估助力医保药品准入的启示

马勇; 刘梦娜; 艾丹丹; 许倩; 齐鲁; 郭武栋

doi:10.19546/j.issn.1674-3830.2022.6.026

中国医疗保险 ›› 2022, Vol. 0 ›› Issue (6) : 125-127. DOI: 10.19546/j.issn.1674-3830.2022.6.026

国际（地区）比较

加拿大卫生技术评估助力医保药品准入的启示

马勇¹, 刘梦娜¹, 艾丹丹², 许倩², 齐鲁¹, 郭武栋¹

作者信息 +

Enlightenment of HTA-driven Drug Access to Medical Insurance in Canada

Author information +

文章历史 +

摘要

加拿大在借助卫生技术评估结果进行医保药品准入决策工作方面积累了一定经验,本文对其管理机制和技术要点进行系统梳理,为完善我国医保药品准入工作提供参考。

Abstract

Canada has accumulated some experience in decision-making of medical insurance drug access based on the results of health technology assessment. This paper systematically sorts out its management mechanism and technical points to provide reference for improving China's medical insurance drug access.

导出引用

马勇, 刘梦娜, 艾丹丹, 许倩, 齐鲁, 郭武栋. 加拿大卫生技术评估助力医保药品准入的启示[J]. 中国医疗保险. 2022, 0(6): 125-127 https://doi.org/10.19546/j.issn.1674-3830.2022.6.026

Enlightenment of HTA-driven Drug Access to Medical Insurance in Canada[J]. China Health Insurance. 2022, 0(6): 125-127 https://doi.org/10.19546/j.issn.1674-3830.2022.6.026

中图分类号： F840.684C913.7

参考文献

[1] Nicola Allen,Stuart R,Lawrence Liberti,et al.Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study[J].CMAJ OPEN,2016,4(4):674-678.
[2] CADTH.Procedures for CADTH Reimbursement Reviews[R].2022,3.
[3] CADTH.Procedures for the CADTH pan-Canadian Oncology Drug Review[R].2020,6.
[4] 周挺,李洪超,马爱霞,等.加拿大药品统一审评制度及价格管理体系简析[J].中国卫生经济,2018,(37)2:94-96.
[5] 王梦骁,邵蓉.加拿大统一药品审评制度的效果评价及启示[J].卫生经济研究,2016,(4) :41-44
[6] 常峰,席悦,李世勇,等.加拿大品牌药价格联合谈判机制及其对我国的启示[J].价格管理与实践,2016,(3):83-86.